You are here

Oral Diabetes Treatment Semaglutide Enters Phase III Trial

Study scheduled for early 2016

Novo Nordisk is set to begin a phase III study of semaglutide, its diabetes drug that can be taken orally rather than by injection, after “encouraging” results were reported in previous trials, according to a report from Reuters.

Semaglutide is a glycagon-like peptide-1 (GLP-1) antagonist.

Novo also initiated the development of the world’s first once-weekly insulin injection last year.

In a 26-week, phase II study, reported in February, diabetic patients treated with 40 mg of oral semaglutide demonstrated a 1.9% reduction in hemoglobin A1C (HbA1C), a marker of glucose levels. In comparison, 1 mg of weekly injected semaglutide also resulted in a 1.9% reduction in HbA1C, and placebo lowered HbA1C by 0.3%. At that time, Novo said the oral version also led to weight loss comparable with that of weekly semaglutide, which helped patients lose more than 14 pounds from a baseline of approximately 203 pounds.

The first study in the phase III PIONEER program will begin in the first quarter of 2016 and will investigate the efficacy and safety of once-daily oral semaglutide doses of 3 mg, 7 mg, and 14 mg compared with sitagliptin (100 mg once daily). The remaining six trials in the program are also expected to be initiated during 2016.

Approximately 387 million people have diabetes worldwide, according to the International Diabetes Federation, a number expected to increase by 205 million by 2035.

Source: Reuters; August 26, 2015.

More Headlines

First and Only Treatment Reduces Depressive Symptoms Within Days
Bone Marrow Cleared of Leukemia in Almost 60% of Patients
Combination of Two Drugs Could Reduce Tumor Growth
Atezolizumab in Combination with Chemotherapy is the Only First-line Cancer Immunotherapy for ES-SCLC
Pre-clinical Trials Showed Drug Inhibits Fibroblast Activity and Collagen Deposition
PARG Inhibitor Exploits Weakness, Kills Cells
Inexpensive, Wearable Therapy Increases Arm Mobility, Reduces Stiffness
FDA Prioritizing Review of ARB Applications to Help Mitigate Drug Shortage